Tumor-associated antigens from autologous high-grade glioma lysate (ATL)

Tumor-associated antigens from autologous high-grade glioma lysate consist of a personalized collection of proteins and peptides derived directly from a patient's surgically resected tumor tissue. This lysate serves as a comprehensive antigenic library, encompassing both well-characterized tumor-associated antigens (TAAs) and unique, patient-specific neoantigens (Liau et al., 2023). In clinical applications, such as dendritic cell vaccines like DCVax-L, these antigens are used to pulse or load immune cells, which are then re-administered to the patient to trigger a robust, polyclonal T-cell response (Siavoshian et al., 2023). This approach is specifically designed to address the high degree of intratumoral heterogeneity characteristic of high-grade gliomas, such as glioblastoma multiforme (Prins et al., 2011). By targeting a broad spectrum of antigens simultaneously, the therapy aims to prevent 'antigen escape' and improve overall survival in patients with these aggressive brain tumors (Liau et al., 2018).

Other names

Autologous tumor lysateATLHigh-grade glioma lysateGlioblastoma multiforme lysatePatient-specific tumor antigensHGG lysate

The lysate serves as a source of diverse tumor-associated antigens (TAAs) and neoantigens that are loaded onto dendritic cells or administered directly to prime the patient's immune system. This induces a polyclonal cytotoxic T-lymphocyte (CTL) response and helper T-cell activation specifically directed against the unique antigenic profile of the individual's tumor (Liau et al., 2023; NIH ClinicalTrials.gov).